Objectives The introduction of new oral anticoagulants for the prevention of stroke in atrial
fibrillation (AF) has changed the clinical management of AF. To inform decision making …

INTRODUCTION AND OBJECTIVES: Assessment of the cost-effectiveness of dabigatran for
the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation …

Abstract Introduction and Objectives To estimate the cost-effectiveness and cost-utility of
dabigatran in the prevention of stroke and systemic embolism in patients with non-valvular …

Background: Dabigatran exilate has emerged as a highly effective tool in treating atrial
fibrillation, AF). Its relative convenience in terms of cost and overall utility with respect to …

Background. Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered
in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial …

Aims Patients with atrial fibrillation have a significantly increased risk of thromboembolic
events such as ischaemic stroke, and patients are therefore recommended to be treated with …

Objectives Management with vitamin K antagonists (VKAs) has been an effective and cost-
effective strategy for stroke prevention in atrial fibrillation (AF) but is associated with …

Oral dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in
patients with atrial fibrillation (AF) in whom anticoagulation is appropriate. Based on the RE …

Objectives Gold standard treatment for stroke prevention in atrial fibrillation in Spain are
vitamin K antagonists (VKA), such as warfarin. They are a low-priced choice, but have …

Background Oral dabigatran etexilate is indicated for the prevention of systemic
thromboembolic events in patients with non-valvular atrial fibrillation (NVAF). Based on the …